Clinical trialPhase 2Completed
Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
A Phase II Clinical and Translational Study of MK-2206 in Patients With Metastatic Neuroendocrine Tumors (NET)
- Outcome
- Outcome unknown
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- July 2010
- Expected end
- February 2014
- Enrollment
- 11 participants
- Sites
- 1
- Primary outcomes
- Overall Response.
- Sponsor
- Other
- Results posted
- 2016-02-18
- Last update
- 18 February 2016
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The purpose of this study is to test a new drug called MK-2206. This study is a phase II study. In cancer studies, a phase II study is to find out what effects, good and/or bad, a new treatment has against a certain type of cancer. MK-2206 is an oral medication known as a targeted therapy. By attaching to the target, we hope that MK-2206 may stop the cancer cells from further growth and dividing. This study will help find out if MK-2206 is a helpful drug when taken in patients with neuroendocrine tumor.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Overall Response. [every 12 weeks]. Number, participants. Stable Disease: MK-2206 in Patients With Metastatic Neuroendocrine Tumors (n=8): 6. Progression of Disease: MK-2206 in Patients With Metastatic Neuroendocrine Tumors (n=8): 2.